Diabetic Macular Edema Market Introduction and Overview
According to SPER Market Research, the Global Diabetic Macular Edema Market is estimated to reach USD 15.25 billion by 2033 with a CAGR of 4.69%.
The report includes an in-depth analysis of the Global Diabetic Macular Edema Market, including market size and trends, product mix, applications, and supplier analysis. Macular edema is a condition that impairs vision and may result in vision loss when there is an abnormal leakage and accumulation of fluid from injured blood vessels in the surrounding retina in the macula. There are two forms of macular edema: diabetic macular edema and cystoid macular edema. Furthermore, macular degeneration, a disorder caused by retinal damage that results in loss of central vision, is a painless illness condition that primarily affects persons over 50 or the elderly population. There are two forms of macular degeneration: wet macular degeneration and dry macular degeneration. The number of cases of macular edema and degeneration is rising due to the aging population, which is a factor driving the market's expansion.
- December 2018; A new drug called XIPERE was submitted by Clearside Biomedical to treat retinal edema brought on by uveitis.
- May 2021; The late-stage medications faricimab (Roche), KSI 301 (Kodiak Sciences Inc.), and Beovu (Novartis) have demonstrated encouraging outcomes in diabetic macular edema and are anticipated to enhance the dosage interval.
Market Opportunities and Challenges
An increase in the number of R&D-related projects:
Moreover, the market is growing due to a rise in research and development activities. The market for diabetic macular edema (DME) will benefit from these favorable conditions. The growing number of new approvals and launches for diabetic macular edema (DME) medications will help boost the market's growth rate. Furthermore, due to increased investment in the development of cutting-edge technologies and an increase in the number of new markets, there will be good opportunities for the diabetic macular edema (DME) market to expand throughout the course of the projection period.
Conversely, the elevated expense linked to the management of diabetic macular edema (DME) will hinder the market's growth trajectory. The diabetic macular edema (DME) industry will face challenges from a lack of qualified personnel and a weak healthcare infrastructure in underdeveloped nations. In markets where cost-cutting measures are being used more frequently, expensive therapies will encounter difficulties in receiving reimbursement. Furthermore, many patients will continue to lack sufficient angiogenesis suppression due to the pipeline medicines' subpar performance. This could impede the target market's expansion in the upcoming years. Moreover, All patients with diabetes mellitus should have yearly, or at least every other year, ophthalmic examinations.
Market Competitive Landscape
Leading companies in the market for diabetic macular edema are concentrating on intensive R&D. A sizable trial pipeline is presently in place for diabetic macular edema therapy formulations. Before a product is distributed, its patent and licensing status serve as a crucial differentiator between established companies and up-and-coming rivals. The major key playes that involved in the market are Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical, Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Treatment Type, By Application, By End User
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical,Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,
|
COVID-19 Impact on Global Diabetic Macular Edema Market
The COVID-19 virus first appeared in December 2019 and has since spread to almost every nation on the earth, leading the World Health Organization (WHO) to declare a public health emergency. Global healthcare systems have been severely impacted in the aftermath of the coronavirus pandemic because of the financial crisis and the delay in providing specialty healthcare while giving priority to COVID-19-related treatments. Due to pandemic constraints, patients were unable to see their controls for a number of reasons, such as difficulties finding a doctor, fear of illness transfer, and inability to continue important surgeries and therapies. These factors can have a detrimental effect on the diabetic macular edema (DME) market in the upcoming months.
Key Target Audience:
- Patients with Diabetic Macular Edema
- Ophthalmologists and Retinal Specialists
- Healthcare Providers and Payers
- Pharmaceutical and Device Companies
- Research Institutions and Academia
Our in-depth analysis of the Diabetic Macular Edema Market includes the following segments:
|
By Treatment Type: |
Drug Therapy
Laser Treatment
|
|
By Application: |
Macular Edema
Macular Degeneration
|
|
By End User: |
Hospital
Clinics
Others
|
Key Topics Covered in the Report:
- Global Diabetic Macular Edema Market Size (FY’2024-FY’2033)
- Overview of Global Diabetic Macular Edema Market
- Segmentation of Global Diabetic Macular Edema Market By Treatment Type (Drug Therapy and Laser Treatment)
- Segmentation of Global Diabetic Macular Edema Market By Application (Macular Edema and Macular Degeneration)
- Segmentation of Global Diabetic Macular Edema Market By End User(Hospital, Clinics and Other)
- Statistical Snap of Global Diabetic Macular Edema Market
- Expansion Analysis of Global Diabetic Macular Edema Market
- Problems and Obstacles in Global Diabetic Macular Edema Market
- Competitive Landscape in the Global Diabetic Macular Edema Market
- Impact of COVID-19 and Demonetization on Global Diabetic Macular Edema Market
- Details on Current Investment in Global Diabetic Macular Edema Market
- Competitive Analysis of Global Diabetic Macular Edema Market
- Prominent Players in the Global Diabetic Macular Edema Market
- SWOT Analysis of Global Diabetic Macular Edema Market
- Global Diabetic Macular Edema Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Diabetic Macular Edema Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Diabetic Macular Edema Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Macular Edema Market
7. Global Diabetic Macular Edema Market, By Treatment Type (USD Million)
7.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Treatment Type, 2024-2033
7.2. Drug Therapy
7.3. Laser Treatment
8. Global Diabetic Macular Edema Market, By Application (USD Million)
8.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Application, 2024-2033
8.2. Macular Edema
8.3. Macular Degeneration
9. Global Diabetic Macular Edema Market, By End User (USD Million)
9.1. Global Diabetic Macular Edema Market Value Share and Forecast, By End User, 2024-2033
9.2. Hospital
9.3. Clinics
9.4. Others
10. Global Diabetic Macular Edema Market Forecast, 2020-2033 (USD Million)
10.1. Global Diabetic Macular Edema Market Size and Market Share
11. Global Diabetic Macular Edema Market, By Treatment Type 2020-2033 (USD Million)
11.1. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2020-2026)
11.2. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2027-2033)
12. Global Diabetic Macular Edema Market, By Application, 2020-2033 (USD Million)
12.1. Global Diabetic Macular Edema Market Size and Market Share By Application (2020-2026)
12.2. Global Diabetic Macular Edema Market Size and Market Share By Application (2027-2033)
13. Global Diabetic Macular Edema Market, By End User, 2019-2033 (USD Million)
13.1. Global Diabetic Macular Edema Market Size and Market Share By End User (2020-2026)
13.2. Global Diabetic Macular Edema Market Size and Market Share By End User (2027-2033)
14. Global Diabetic Macular Edema Market, By Region, 2019-2033 (USD Million)
14.1. Global Diabetic Macular Edema Market Size and Market Share By Region (2020-2026)
14.2. Global Diabetic Macular Edema Market Size and Market Share By Region (2027-2033)
14.3. Asia-Pacific
14.3.1. Australia
14.3.2. China
14.3.3. India
14.3.4. Japan
14.3.5. South Korea
14.3.6. Rest of Asia-Pacific
14.4. Europe
14.4.1. France
14.4.2. Germany
14.4.3. Italy
14.4.4. Spain
14.4.5. United Kingdom
14.4.6. Rest of Europe
14.5. Middle East and Africa
14.5.1. Kingdom of Saudi Arabia
14.5.2. United Arab Emirates
14.5.3. Rest of Middle East & Africa
14.6. North America
14.6.1. Canada
14.6.2. Mexico
14.6.3. United States
14.7. Latin America
14.7.1. Argentina
14.7.2. Brazil
14.7.3. Rest of Latin America
15. Company Profile
15.1. Alimera Sciences Inc.
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary
15.1.4. Recent developments
15.2. Abbvie Inc.
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary
15.2.4. Recent developments
15.3. Bayer AG
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary
15.3.4. Recent developments
15.4. Bausch Health Companies Inc.
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary
15.4.4. Recent developments
15.5. F. Hoffmann-La Roche Ltd
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary
15.5.4. Recent developments
15.6. GlaxoSmithKline Plc
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary
15.6.4. Recent developments
15.7. Kubota Pharmaceutical Hodlings Co. Ltd.
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary
15.7.4. Recent developments
15.8. Novartis AG
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary
15.8.4. Recent developments
15.9. Regen X Bio Inc.
15.9.1. Company details
15.9.2. Financial outlook
15.9.3. Product summary
15.9.4. Recent developments
15.10. Regeneron Pharmaceuticals Inc.
15.10.1. Company details
15.10.2. Financial outlook
15.10.3. Product summary
15.10.4. Recent developments
15.11. Others
16. List of Abbreviations
17. Reference Links
18. Conclusion
19. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
